Latest Breaking News On - Anne phelan - Page 3 : comparemela.com

BenevolentAI Doses First Participants in Clinical Trial of BEN-8744; Targets PDE10, an AI-derived Novel Target for the Treatment of Ulcerative Colitis

BenevolentAI Doses First Participants in Clinical Trial of BEN-8744; Targets PDE10, an AI-derived Novel Target for the Treatment of Ulcerative Colitis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomNew yorkUnited statesAnne phelanJoanna shieldsCompany euronext amsterdamRajin kang vp communicationsUlcerative colitisEuronext amsterdamChief scientific officerChief executive officerAktien sie

BenevolentAI doses participants in BEN-8744 study

BenevolentAI doses participants in BEN-8744 study
pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.

Joanna shieldsAnne phelan

Carl Simpson receives ten years in prison for Lydd crash which killed three

A man has been sent to prison after a crash which killed a social worker, a beloved husband and an expectant dad.

United kingdomCarl simpsonGeorgie fletcherJustice simon jamesAnne phelanRachel stephensMichael phelanSharon haywoodJack ryle thompsettCanterbury crown courtMrs haywoodDacia duster ambianceCindy swift

BenevolentAI progresses BEN-34712 for ALS treatment

BenevolentAI, a clinical-stage AI development company, has announced the successful delivery of its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS), BEN-34712.

Richard meadAnne phelanSheffield institute for translational neuroscience sitraUniversity of sheffieldSheffield instituteTranslational neuroscienceBio developmentsArtificial intelligenceClinical trialsDrug discovery

Mixed results from latest study of BenevolentAI s dermatitis ointment

An ointment for patients with mild to moderate skin disease, atopic dermatitis (AD), has had mixed results from its phase 2a study.

Anne phelanEczema areaSeverity indexClinical developmentDrug deliveryTransparency on trialPis active pharmaceutical ingredientsDelivery formulationsHasei iiSkin diseasesClinical trial